Measurement of molecular biomarkers to predict tumor response in estrogen receptor positive breast cancer after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy

Date

10 Oct 2016

Session

Poster display

Presenters

Kun Wang

Citation

Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364

Authors

K. Wang1, T. Zhu2, C. Yang2, Y. Zhang2, L. Zhang2

Author affiliations

  • 1 The Second Department Of Breast Cancer, Guangdong General Hospital, 510000 - Guangzhou/CN
  • 2 The Second Department Of Breast Cancer, Guangdong General Hospital, 510120 - Guangzhou/CN
More

Resources

Background

Dose-dense (biweekly) paclitaxel/carboplatin(PC) as neoadjuvant Chemotherapy (NCT) for operable breast cancer is feasible and efficient. This study was to analysis the relationship between the molecular biomarkers and tumor response in estrogen receptor(ER) positive breast cancer.

Methods

84 ER-positive breast cancer patients treated with Dose-dense (biweekly) paclitaxel/carboplatin NCT were analyzed for expression of progesrone receptor (PgR), Tau, ki67, HER2, Bcl-2 by immunohistochemistry (IHC), these data were used to test whether these biomarkers can predict tumor response. The primary endpoint was a pathologically complete response (pCR). The second endpoint was the change in tumor size between pre and post NCT.

Results

Univariate analysis showed that HER2 positive (53.85% vs 8.62%, p 

Conclusions

This study investigates the value of traditional biological markers, Bcl-2 and Tau in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.

Clinical trial identification

NCT02059876

Legal entity responsible for the study

N/A

Funding

Guangdong General Hospital

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings